Entrada Therapeutics, Inc. (TRDA)

Entrada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	210.78	129.01	-	-	-
Revenue Growth (YoY)	63.38%	-	-	-	-
Cost of Revenue	125.31	99.88	66.61	35.93	-
Gross Profit	85.48	29.13	-66.61	-35.93	-
Selling, General & Admin	38.47	32.29	30.64	15.2	5.57
Research & Development	-	-	-	-	21.1
Operating Expenses	38.47	32.29	30.64	15.2	26.67
Operating Income	47.01	-3.16	-97.25	-51.13	-26.67
Interest & Investment Income	19.47	15.22	2.63	0.04	0.16
EBT Excluding Unusual Items	66.49	12.06	-94.62	-51.08	-26.5
Gain (Loss) on Sale of Assets	-	-	-	-0.07	-0.02
Pretax Income	66.49	12.06	-94.62	-51.16	-26.52
Income Tax Expense	0.86	18.74	-	-	-
Net Income	65.63	-6.69	-94.62	-51.16	-26.52
Net Income to Common	65.63	-6.69	-94.62	-51.16	-26.52
Shares Outstanding (Basic)	37	33	31	6	1
Shares Outstanding (Diluted)	39	33	31	6	1
Shares Change (YoY)	18.01%	5.62%	399.27%	467.09%	18.45%
EPS (Basic)	1.76	-0.20	-3.02	-8.16	-24.00
EPS (Diluted)	1.68	-0.20	-3.02	-8.16	-24.00
Free Cash Flow	-44.72	134.19	-96.67	-55.44	-27.89
Free Cash Flow Per Share	-1.15	4.06	-3.09	-8.85	-25.23
Gross Margin	40.55%	22.58%	-	-	-
Operating Margin	22.30%	-2.45%	-	-	-
Profit Margin	31.14%	-5.18%	-	-	-
Free Cash Flow Margin	-21.21%	104.01%	-	-	-
EBITDA	50.78	-0.32	-95.35	-50.01	-26.34
EBITDA Margin	24.09%	-0.25%	-	-	-
D&A For EBITDA	3.77	2.84	1.9	1.12	0.33
EBIT	47.01	-3.16	-97.25	-51.13	-26.67
EBIT Margin	22.30%	-2.45%	-	-	-
Effective Tax Rate	1.29%	155.45%	-	-	-

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q